LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Net Change in Cash

Last Annual Value

227.19M

3-Year CAGR

123%

5-Year CAGR

62%

10-Year CAGR

27%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Net Change in Cash

LBRX · NASDAQ
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
227.19M
N/AN/AN/A 
27.82M
N/A-26.7%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
112.55M
9.8%N/AN/A
13.90M
N/A-26.3%-10.5%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-44.44M
N/AN/AN/A
27.47M
N/A-11.0%N/A
-45.52M
N/AN/AN/A
36.66M
-3.4%-21.5%N/A
96.22M
N/AN/AN/A
-86.10M
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
-33.82M
N/AN/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95